ORAI1 and alkaline phosphatase measurement: Because of these findings, ORAI1 inhibitors are currently under active clinical development to treat AP.6 Although the acinar cells have traditionally been the primary focus when considering the pathophysiology of AP, it has been proposed that the primary Ca2+-dependent injury of the acinar cells triggers processes in adjacent stellate and immune cells that create necrotic amplification loops.2 Nevertheless, little is still known about ORAI1 cell-specific effects.